Gilead Sciences EPS - Earnings per Share 2010-2022 | GILD
Gilead Sciences annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Gilead Sciences EPS for the quarter ending March 31, 2022 was $0.02, a 98.54% decline year-over-year.
- Gilead Sciences EPS for the twelve months ending March 31, 2022 was $3.58, a 1332% increase year-over-year.
- Gilead Sciences 2021 annual EPS was $4.93, a 4830% increase from 2020.
- Gilead Sciences 2020 annual EPS was $0.1, a 97.63% decline from 2019.
- Gilead Sciences 2019 annual EPS was $4.22, a 1.2% increase from 2018.
| Gilead Sciences Annual EPS |
| 2021 |
$4.93 |
| 2020 |
$0.10 |
| 2019 |
$4.22 |
| 2018 |
$4.17 |
| 2017 |
$3.51 |
| 2016 |
$9.94 |
| 2015 |
$11.91 |
| 2014 |
$7.35 |
| 2013 |
$1.81 |
| 2012 |
$1.64 |
| 2011 |
$1.77 |
| 2010 |
$1.66 |
| 2009 |
$1.41 |
| Gilead Sciences Quarterly EPS |
| 2022-03-31 |
$0.02 |
| 2021-12-31 |
$0.30 |
| 2021-09-30 |
$2.05 |
| 2021-06-30 |
$1.21 |
| 2021-03-31 |
$1.37 |
| 2020-12-31 |
$1.25 |
| 2020-09-30 |
$0.29 |
| 2020-06-30 |
$-2.66 |
| 2020-03-31 |
$1.22 |
| 2019-12-31 |
$2.13 |
| 2019-09-30 |
$-0.92 |
| 2019-06-30 |
$1.47 |
| 2019-03-31 |
$1.54 |
| 2018-12-31 |
$0.01 |
| 2018-09-30 |
$1.60 |
| 2018-06-30 |
$1.39 |
| 2018-03-31 |
$1.17 |
| 2017-12-31 |
$-2.93 |
| 2017-09-30 |
$2.06 |
| 2017-06-30 |
$2.33 |
| 2017-03-31 |
$2.05 |
| 2016-12-31 |
$2.34 |
| 2016-09-30 |
$2.49 |
| 2016-06-30 |
$2.58 |
| 2016-03-31 |
$2.53 |
| 2015-12-31 |
$3.17 |
| 2015-09-30 |
$3.06 |
| 2015-06-30 |
$2.92 |
| 2015-03-31 |
$2.76 |
| 2014-12-31 |
$2.15 |
| 2014-09-30 |
$1.67 |
| 2014-06-30 |
$2.20 |
| 2014-03-31 |
$1.33 |
| 2013-12-31 |
$0.45 |
| 2013-09-30 |
$0.47 |
| 2013-06-30 |
$0.46 |
| 2013-03-31 |
$0.43 |
| 2012-12-31 |
$0.47 |
| 2012-09-30 |
$0.43 |
| 2012-06-30 |
$0.46 |
| 2012-03-31 |
$0.28 |
| 2011-12-31 |
$0.43 |
| 2011-09-30 |
$0.48 |
| 2011-06-30 |
$0.47 |
| 2011-03-31 |
$0.40 |
| 2010-12-31 |
$0.39 |
| 2010-09-30 |
$0.42 |
| 2010-06-30 |
$0.40 |
| 2010-03-31 |
$0.46 |
| 2009-12-31 |
$0.43 |
| 2009-09-30 |
$0.36 |
| 2009-06-30 |
$0.31 |
| 2009-03-31 |
$0.32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$79.360B |
$27.305B |
|
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
|
